Efficacy and tolerability of cefetamet pivoxil in diabetic patients with urinary tract infections: a case-control study.

Cefetamet pivoxil, an oral third generation cephalosporin, was evaluated in 218 hospitalized patients with complicated urinary tract infections. Among these patients, 28 (13.1%) were suffering from concomitant diabetes: 25 of these patients were matched with 25 non-diabetic patients and for each pair, the age +/- 2 years, sex, complicating factors, etc. had to be identical. All patients received 2000 mg cefetamet pivoxil daily for 10 days. The predominant pathogen was E. coli; 18 in the diabetic group, 15 among non-diabetics. Comparison of the therapeutic results showed that the bacteriological eradication rate was similar in diabetic and non-diabetic patients, 92% and 87.5%, respectively. There was a similar improvement in pyuria, and therapeutic response was equal in diabetic patients as in non-diabetic patients. No unwanted effects on renal function were observed in the high-risk diabetic group.